Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade (Q36649671)

15 August 2017

1 reference

title

Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade (English)

1 reference

15 August 2017

Dandona P

1

1 reference

15 August 2017

Dhindsa S

series ordinal

2

1 reference

15 August 2017

Ghanim H

series ordinal

3

1 reference

15 August 2017

Chaudhuri A

series ordinal

4

1 reference

15 August 2017

9 November 2006

1 reference

Journal of Human Hypertension

15 August 2017

1 reference

15 August 2017

21

1 reference

15 August 2017

1

1 reference

15 August 2017

20-27

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1002101

15 August 2017

0 references

cites work

The role of the AT2 receptor in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Mechanisms linking angiotensin II and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Endothelial function. From vascular biology to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Nitric oxide: an endogenous modulator of leukocyte adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Role of the renin-angiotensin system in vascular diseases: expanding the field.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Interactions between the components of the human NADPH oxidase: intrigues in the phox family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

C-reactive protein: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Lisinopril and nifedipine administration inhibits the ex vivo uptake of [45Ca2+] by platelets from hypertensive diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II AT(1) receptor antagonists and platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

C-reactive protein in heart failure: prognostic value and the effect of valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Angiotensin receptor blockade decreases markers of vascular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002101

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002101

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference